HomeCompareMMIRF vs JEPQ

MMIRF vs JEPQ: Dividend Comparison 2026

MMIRF yields 4444.44% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MMIRF wins by $19857738408180.43M in total portfolio value
10 years
MMIRF
MMIRF
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full MMIRF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — MMIRF vs JEPQ

📍 MMIRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMMIRFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MMIRF + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MMIRF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MMIRF
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, MMIRF beats the other by $16,163,659,443,174,255,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MMIRF + JEPQ for your $10,000?

MMIRF: 50%JEPQ: 50%
100% JEPQ50/50100% MMIRF
Portfolio after 10yr
$9928869204090.26M
Annual income
$9,508,034,966,573,095,000.00/yr
Blended yield
95.76%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MMIRF buys
0
JEPQ buys
0
No recent congressional trades found for MMIRF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMMIRFJEPQ
Forward yield4444.44%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$19857738408180.48M$44.8K
Annual income after 10y$19,016,069,933,146,186,000.00$2,152.59
Total dividends collected$19800558376185.16M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MMIRF vs JEPQ ($10,000, DRIP)

YearMMIRF PortfolioMMIRF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$455,144$444,444.44$11,930$1,110.39+$443.2KMMIRF
2$19,392,277$18,905,272.87$14,133$1,224.34+$19.38MMMIRF
3$773,548,232$752,798,494.96$16,632$1,340.46+$773.53MMMIRF
4$28,891,953,466$28,064,256,857.57$19,454$1,457.97+$28891.93MMMIRF
5$1,010,538,077,568$979,623,687,360.21$22,626$1,576.08+$1010538.05MMMIRF
6$33,103,483,882,921$32,022,208,139,922.89$26,175$1,694.09+$33103483.86MMMIRF
7$1,015,787,352,937,823$980,366,625,183,097.90$30,133$1,811.32+$1015787352.91MMMIRF
8$29,201,617,438,828,424$28,114,724,971,184,950.00$34,531$1,927.17+$29201617438.79MMMIRF
9$786,606,051,433,916,900$755,360,320,774,370,600.00$39,403$2,041.08+$786606051433.88MMMIRF
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$44,787$2,152.59+$19857738408180.43MMMIRF

MMIRF vs JEPQ: Complete Analysis 2026

MMIRFStock

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

Full MMIRF Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this MMIRF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MMIRF vs SCHDMMIRF vs JEPIMMIRF vs OMMIRF vs KOMMIRF vs MAINMMIRF vs XYLDMMIRF vs QYLDMMIRF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.